KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Other Non-Current Assets data on record, last reported at $7.6 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 20.43% year-over-year to $7.6 million; the TTM value through Dec 2025 reached $7.6 million, down 20.43%, while the annual FY2025 figure was $7.6 million, 20.43% down from the prior year.
  • Other Non-Current Assets reached $7.6 million in Q4 2025 per JAZZ's latest filing, down from $103.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $103.1 million in Q3 2025 and bottomed at $4.4 million in Q3 2024.
  • Average Other Non-Current Assets over 5 years is $29.8 million, with a median of $11.7 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: tumbled 91.31% in 2024, then soared 2245.12% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $40.8 million in 2021, then skyrocketed by 35.1% to $55.1 million in 2022, then plummeted by 88.25% to $6.5 million in 2023, then soared by 46.48% to $9.5 million in 2024, then dropped by 20.43% to $7.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $7.6 million in Q4 2025, $103.1 million in Q3 2025, and $8.5 million in Q2 2025.